South African pharmaceutical company Aspen Pharmacare said on Monday it had entered into a preliminary agreement with Johnson & Johnson to commercially manufacture its COVID-19 vaccine candidate. Aspen said it had agreed to provide capacity required for the manufacture of J&Jâ€™s vaccine candidate, which is still undergoing clinical trials, at its Port Elizabeth facility. Aspen will perform formulation, filling and secondary packaging of the vaccine for supply to Johnson & Johnson, the company said. Subscribe for full access to all our share and unit trust data tools, our award-winning articles, and support quality journalism in the process. You will be redirected to a checkout page.
To view all features and options, click here. A monthly subscription is charged pro rata, based on the day of purchase. This is non-refundable and includes a R5 once-off sign-up fee.
A yearly subscription is refundable within 14 days of purchase and includes a 365-day membership.